Dr Danielle Borg

Danielle is the program coordinator for the QLD family cohort study at the Mater Research Institute. Her passion in medical research was sparked during her PhD in type 1 diabetes with a leading immunologist in Germany, at the Centre for Regenerative Therapies, Technische Universität Dresden. Her interest in chronic disease continued in Australia into type 1 diabetes therapeutics, focusing on advanced glycation end product biochemical pathways, and type 2 diabetes therapeutics, focusing on interleukin-22, under the mentorship of highly-cited biochemists and immunologists. She has 10 years of research experience in the fields of Diabetes, Cell Transplantation, Cell Imaging and Biochemistry. Throughout her research career, she published peer-reviewed publications, obtained funding for projects, and enjoyed the collaborative nature of medical research.

Danielle’s interest lies in improving health outcomes to the community via the translation of innovative findings from basic and clinical research. This overarching interest prompted her move to clinical research and study coordination in projects focusing on developmental origins of disease, maternal health and pregnancy and child outcomes, after the birth of her first child. She thrives on scientific communication and is an avid believer in giving back to the wider scientific community sitting on numerous committees, grant reviewing and has volunteered for several organisations. Danielle is excited to be a part of a longitudinal birth cohort study which will allow QLD, her home state, to collaborate with other national birth cohort studies and provide relevant information provided by QLD families to help understand how to improve health and child outcomes for years to come.